AC Immune (NASDAQ:ACIU) Stock Passes Below Fifty Day Moving Average – Here’s What Happened

Shares of AC Immune SA (NASDAQ:ACIU) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.00 and traded as low as $2.56. AC Immune shares last traded at $2.64, with a volume of 224,004 shares traded.

Analysts Set New Price Targets

A number of research firms have commented on ACIU. StockNews.com downgraded shares of AC Immune from a “buy” rating to a “hold” rating in a research report on Tuesday, October 1st. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of AC Immune in a research report on Friday, November 15th.

AC Immune Stock Down 1.5 %

The firm’s 50-day moving average price is $3.00 and its two-hundred day moving average price is $3.26. The firm has a market capitalization of $261.20 million, a PE ratio of -5.74 and a beta of 1.29.

Institutional Investors Weigh In On AC Immune

A number of hedge funds have recently added to or reduced their stakes in ACIU. Renaissance Technologies LLC raised its position in shares of AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after acquiring an additional 136,300 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of AC Immune by 63.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after acquiring an additional 7,400 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of AC Immune in the 2nd quarter valued at approximately $218,000. Finally, Geode Capital Management LLC raised its position in shares of AC Immune by 6.4% in the 3rd quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock valued at $220,000 after acquiring an additional 3,499 shares during the period. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.